0.8141USD-8.53%Mkt Cap: 36.93M USDP/E: —Last update: 2026-05-26
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's a…
Industry Peers
Medical Devices151.38BUSDP/E 24.3
119.84BUSDP/E 36.2
86.12BUSDP/E 24.2
54.95BSEKP/E 101.9
53.92BSEKP/E 22.9
52.13BDKKP/E 22.1
50.54BUSDP/E 47.4
39.31BEURP/E 18.6
Indicators:|
Key Statistics
Company
Market Cap36.93M USD
Enterprise Value57.62M USD
Revenue (TTM)80.81M USD
Gross Profit54.34M USD
Net Income (TTM)-38.83M USD
Revenue/Share1.618 USD
Last Price0.8141 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees218
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.66
PEG—
EV/EBITDA-1.76
EV/Revenue0.71
P/S0.51
P/B6.50
EPS (TTM)-0.79
EPS (Forward)-0.56
52W Range
0.501018% of range2.200
52W High2.200 USD
52W Low0.5010 USD
Profitability
Gross Margin67.69%
Oper. Margin-55.23%
EBITDA Margin-40.60%
Profit Margin-48.37%
ROE-615.10%
ROA-47.69%
Growth
Revenue Growth2.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.22M USD
CapEx (TTM)448.00K USD
FCF Margin—
FCF Yield—
Net Debt16.32M USD
Net Debt/EBITDA-0.50
Balance Sheet
Debt/Equity8.90
Current Ratio3.61
Quick Ratio2.76
Book Value/Sh0.1420 USD
Cash/Share0.8830 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)2.250 USD
Target Range1.000 USD – 3.250 USD
# Analysts5
Ownership
Shares Out.44.77M
Float19.48M
Insiders8.42%
Institutions68.99%
Short Interest
Short Ratio4.1d
Short % Float2.48%
Short % Out.1.71%
Shares Short765.76K
Short (prev mo.)690.94K
Technical
SMA 500.7782 (+4.6%)
SMA 2001.133 (-28.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)209.91K
Avg Vol (10d)150.97K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—